Cargando…

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis

Human immunoglobulin (Ig) G4 usually displays antiinflammatory activity, and observations of IgG4 autoantibodies causing severe autoimmune disorders are therefore poorly understood. In blood, IgG4 naturally engages in a stochastic process termed “Fab-arm exchange” in which unrelated IgG4s exchange h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vergoossen, Dana L. E., Plomp, Jaap J., Gstöttner, Christoph, Fillié-Grijpma, Yvonne E., Augustinus, Roy, Verpalen, Robyn, Wuhrer, Manfred, Parren, Paul W. H. I., Dominguez-Vega, Elena, van der Maarel, Silvère M., Verschuuren, Jan J., Huijbers, Maartje G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2021
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020787/ https://www.ncbi.nlm.nih.gov/pubmed/33753489 http://dx.doi.org/10.1073/pnas.2020635118

Ejemplares similares

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK
por: Lim, Jamie L., et al.
Publicado: (2023)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
por: Bhaskar, Shalini, et al.
Publicado: (2022)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
por: Rodolico, Carmelo, et al.
Publicado: (2020)

Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis
por: Kwon, Young Nam, et al.
Publicado: (2022)

Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis
por: Kim, Seung Woo, et al.
Publicado: (2017)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
por: Zhang, Zunwei, et al.
Publicado: (2020)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
por: Huang, Qi, et al.
Publicado: (2022)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
por: Lanfranconi, S., et al.
Publicado: (2011)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

The impact of rituximab infusion protocol on the long‐term outcome in anti‐MuSK myasthenia gravis
por: Cortés‐Vicente, Elena, et al.
Publicado: (2018)

Anti-MuSK Positive Myasthenia Gravis with Anti-Lrp4 and Anti-titin Antibodies
por: Yamashita, Rika, et al.
Publicado: (2020)

Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?
por: Bardakov, Sergey N., et al.
Publicado: (2022)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023)

Timing and localization of myasthenia gravis‐related gene expression
por: Vergoossen, Dana L. E., et al.
Publicado: (2021)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019)

Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis
por: Basile, Umberto, et al.
Publicado: (2021)

Effects of the ß2-Adrenoceptor Agonist, Albuterol, in a Mouse Model of Anti-MuSK Myasthenia Gravis
por: Ghazanfari, Nazanin, et al.
Publicado: (2014)

Grave Prognosis of the MuscleSpecific Kinase (MuSK)-positive Myasthenia Gravis (MG): A False Prejudice
por: Hiew, Fu Liong
Publicado: (2020)

Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study
por: Meng, Xin, et al.
Publicado: (2022)

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022)

Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity
por: Shin, Ha Young, et al.
Publicado: (2014)

Altered Active Zones, Vesicle Pools, Nerve Terminal Conductivity, and Morphology during Experimental MuSK Myasthenia Gravis
por: Patel, Vishwendra, et al.
Publicado: (2014)

Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy
por: Deguchi, Kentaro, et al.
Publicado: (2018)

Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
por: Marino, Mariapaola, et al.
Publicado: (2020)

Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China
por: Zhou, Yufan, et al.
Publicado: (2022)

Treating muscle-specific kinase myasthenia gravis from the inside out
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Anti-Muscle Specific Kinase (Anti-MuSK) Positive Myasthenia Gravis Overlapping With Parkinson’s Disease: A Challenging Diagnosis
por: Albassam, Mohammed S, et al.
Publicado: (2021)

A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia
por: Ben Ammar, Asma, et al.
Publicado: (2013)

Myopathy or Myasthenia Positive for Antibodies Against MuSK, Lrp4, and Titin
por: Finsterer, Josef, et al.
Publicado: (2020)

Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis
por: Ghazanfari, Nazanin, et al.
Publicado: (2015)

Comorbid Human Immunodeficiency Virus (HIV) and Muscle-Specific Kinase (MuSK) Myasthenia Gravis: A Case Report and Literature Review
por: Sherpa, Michael, et al.
Publicado: (2017)

Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
por: Ge, XiuShan, et al.
Publicado: (2022)

MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters
por: Koneczny, Inga, et al.
Publicado: (2013)

Correction: A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia
por: Ben Ammar, Asma, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1mseu24p99iaerf9lhqe7u5jk5